111 related articles for article (PubMed ID: 28853141)
1. Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Jipping KM; Hulshoff JB; van Amerongen EA; Bright TI; Watson DI; Plukker JTM
J Surg Oncol; 2017 Dec; 116(8):1096-1102. PubMed ID: 28853141
[TBL] [Abstract][Full Text] [Related]
2. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
4. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
[TBL] [Abstract][Full Text] [Related]
5. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
[TBL] [Abstract][Full Text] [Related]
8. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes.
Xi M; Yang Y; Zhang L; Yang H; Merrell KW; Hallemeier CL; Shen RK; Haddock MG; Hofstetter WL; Maru DM; Ho L; Wu CC; Liu M; Lin SH
Ann Surg; 2019 Apr; 269(4):663-670. PubMed ID: 29334555
[TBL] [Abstract][Full Text] [Related]
9. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
10. Impact of neoadjuvant chemoradiotherapy on the local recurrence and distant metastasis pattern of locally advanced rectal cancer: a propensity score-matched analysis.
Yu L; Xu TL; Zhang L; Shen SH; Zhu YL; Fang H; Zhang HZ
Chin Med J (Engl); 2021 Sep; 134(18):2196-2204. PubMed ID: 34553701
[TBL] [Abstract][Full Text] [Related]
11. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
van Hagen P; Wijnhoven BP; Nafteux P; Moons J; Haustermans K; De Hertogh G; van Lanschot JJ; Lerut T
Br J Surg; 2013 Jan; 100(2):267-73. PubMed ID: 23180560
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
14. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.
van der Wilk BJ; Noordman BJ; Neijenhuis LKA; Nieboer D; Nieuwenhuijzen GAP; Sosef MN; van Berge Henegouwen MI; Lagarde SM; Spaander MCW; Valkema R; Biermann K; Wijnhoven BPL; van der Gaast A; van Lanschot JJB; Doukas M; Nikkessen S; Luyer M; Schoon EJ; Roef MJ; van Lijnschoten I; Oostenbrug LE; Riedl RG; Gisbertz SS; Krishnadath KK; Bennink RJ; Meijer SL;
Ann Surg; 2021 Dec; 274(6):1009-1016. PubMed ID: 31592898
[TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study.
Gronnier C; Tréchot B; Duhamel A; Mabrut JY; Bail JP; Carrere N; Lefevre JH; Brigand C; Vaillant JC; Adham M; Msika S; Demartines N; El Nakadi I; Piessen G; Meunier B; Collet D; Mariette C; ; Luc G; Cabau M; Jougon J; Badic B; Lozach P; Cappeliez S; Lebreton G; Alves A; Flamein R; Pezet D; Pipitone F; Iuga BS; Contival N; Pappalardo E; Mantziari S; Hec F; Vanderbeken M; Tessier W; Briez N; Fredon F; Gainant A; Mathonnet M; Bigourdan JM; Mezoughi S; Ducerf C; Baulieux J; Pasquer A; Baraket O; Poncet G; Vaudoyer D; Enfer J; Villeneuve L; Glehen O; Coste T; Fabre JM; Marchal F; Frisoni R; Ayav A; Brunaud L; Bresler L; Cohen C; Aze O; Venissac N; Pop D; Mouroux J; Donici I; Prudhomme M; Felli E; Lisunfui S; Seman M; Petit GG; Karoui M; Tresallet C; Ménégaux F; Hannoun L; Malgras B; Lantuas D; Pautrat K; Pocard M; Valleur P
Ann Surg; 2014 Nov; 260(5):764-70; discussion 770-1. PubMed ID: 25379847
[TBL] [Abstract][Full Text] [Related]
16. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
[TBL] [Abstract][Full Text] [Related]
17. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
20. Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer.
Thoen H; Ceelen W; Boterberg T; Van Daele E; Pattyn P
Radiother Oncol; 2015 Apr; 115(1):16-21. PubMed ID: 25818394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
